Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477594 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
A Phase 2 study, sponsored by Kastle Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00477594 is a Phase 2 study that has completed, run by Kastle Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT00477594, a Phase 2 study, has completed, sponsored by Kastle Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
Interventions
- DRUG mipomersen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477594
The ClinicalTrials.gov registry entry for NCT00477594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kastle Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mipomersen sodium is the first listed.
NCT00477594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477594 about?
NCT00477594 is a clinical study titled "Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia". The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
What is the current status of trial NCT00477594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2007-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00477594?
The interventions under investigation include: mipomersen sodium (DRUG).
Who is sponsoring clinical trial NCT00477594?
This trial is sponsored by Kastle Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.